Drugs / 177Lu-ST2210
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03188328 | Aug 2017 → Jun 2019 | — | Alfasigma S.p.A. | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 177Lu-ST2210 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03188328 ↗ |
| Route | Intravenous | “Patients will receive an intralesion injection of AvidinOX followed by two intravenous infusions of 177Lu- ST2210 with a distance of 14 days between them” NCT03188328 ↗ |